SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Daniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, Pawel Jan Wiechno, Cora N Sternberg, Kevin Doner, Joaquim Bellmunt, John M Burke, Maria Ochoa de Olza, Ananya Choudhury, Juergen E Gschwend, Evgeny Kopyltsov, Aude Flechon, Nicolas Van As, Nadine Houede, Debora Barton, Abderrahim Fandi, Ulf Jungnelius, Shaoyi Li, Ronald de Wit, Karim Fizazi, Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial, The Lancet Oncology, 2015, 16, 4, 417

    CrossRef

  2. 2
    J. Wang, T. R. McGuire, H. C. Britton, J. K. Schwarz, F. R. Loberiza, J. L. Meza, J. E. Talmadge, Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer, Clinical & Experimental Metastasis, 2015, 32, 2, 111

    CrossRef

  3. 3
    Chadi Nabhan, Anand Patel, Dana Villines, Kathy Tolzien, Susan K. Kelby, Timothy M. Lestingi, Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study, Clinical Genitourinary Cancer, 2014, 12, 1, 27

    CrossRef

  4. 4
    Vu H Duong, Rami S Komrokji, Alan F List, Update on the pharmacotherapy for myelodysplastic syndromes, Expert Opinion on Pharmacotherapy, 2014, 15, 13, 1811

    CrossRef

  5. 5
    Michaela Semeraro, Erika Vacchelli, Alexander Eggermont, Jerome Galon, L Zitvogel, G Kroemer, Lorenzo Galluzzi, Trial Watch: Lenalidomide-based immunochemotherapy, OncoImmunology, 2013, 2, 11, e26494

    CrossRef

  6. 6
    Angela Segler, Apostolia-Maria Tsimberidou, Lenalidomide in solid tumors, Cancer Chemotherapy and Pharmacology, 2012, 69, 6, 1393

    CrossRef

  7. 7
    Norbert Marschner, Matthias Zaiss, Long-Term Disease Stabilization in a Patient with Castration-Resistant Metastatic Prostate Cancer by the Addition of Lenalidomide to Low-Dose Dexamethasone and Celecoxib, Onkologie, 2012, 35, 5, 279

    CrossRef

  8. 8
    Inmaculada Rapado, Juan José Lahuerta, Laura Montejano, María Ángeles Montalbán, Laura Pares, Joaquín Martínez- López, New antimyeloma drugs in spinal cord infiltration for multiple myeloma. Determination of lenalidomide in cerebrospinal fluid with ultrasensitive high-performance liquid chromatography, Modern Chemotherapy, 2012, 01, 02, 11

    CrossRef

  9. 9
    Darlene M. Rozewski, Sarah E. M. Herman, William H. Towns, Emilia Mahoney, Matthew R. Stefanovski, Jungook D. Shin, Xiaoxia Yang, Yue Gao, Xiaobai Li, David Jarjoura, John C. Byrd, Amy J. Johnson, Mitch A. Phelps, Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice, The AAPS Journal, 2012, 14, 4, 872

    CrossRef

  10. 10
    Y. Loriot, C. Massard, K. Fizazi, Recent developments in treatments targeting castration-resistant prostate cancer bone metastases, Annals of Oncology, 2012, 23, 5, 1085

    CrossRef

  11. 11
    N. Chen, C. Kasserra, J. Reyes, L. Liu, H. Lau, Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity, Cancer Chemotherapy and Pharmacology, 2012, 70, 5, 717

    CrossRef

  12. 12
    Ron J. Keizer, Anthe S. Zandvliet, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema, Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152), Investigational New Drugs, 2012, 30, 4, 1519

    CrossRef

  13. 13
    Jerome B. Zeldis, Robert Knight, Mohamad Hussein, Rajesh Chopra, George Muller, A review of the history, properties, and use of the immunomodulatory compound lenalidomide, Annals of the New York Academy of Sciences, 2011, 1222, 1
  14. 14
    Irène Asmane, Jocelyn Céraline, Brigitte Duclos, Lynn Rob, Valère Litique, Philippe Barthélémy, Jean-Pierre Bergerat, Patrick Dufour, Jean-Emmanuel Kurtz, New Strategies for Medical Management of Castration-Resistant Prostate Cancer, Oncology, 2011, 80, 1-2, 1

    CrossRef

  15. 15
    C. Nabhan, B. Parsons, E. Z. Touloukian, W. M. Stadler, Novel approaches and future directions in castration-resistant prostate cancer, Annals of Oncology, 2011, 22, 9, 1948

    CrossRef

  16. 16
    F. Dayyani, G. E. Gallick, C. J. Logothetis, P. G. Corn, Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer, JNCI Journal of the National Cancer Institute, 2011, 103, 22, 1665

    CrossRef

  17. 17
    Mei-Chuan Huang, Nigel H. Greig, Weiming Luo, David Tweedie, Janice B. Schwartz, Dan L. Longo, Luigi Ferrucci, William B. Ershler, Edward J. Goetzl, Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide, Clinical Immunology, 2011, 138, 2, 201

    CrossRef

  18. 18
    Jacek Wilczynski, Markus Duechler, Malgorzata Czyz, Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part I, Archivum Immunologiae et Therapiae Experimentalis, 2011, 59, 4, 289

    CrossRef

  19. 19
    Jeanny B. Aragon-Ching, Ravi A. Madan, William L. Dahut, Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises, Journal of Oncology, 2010, 2010, 1

    CrossRef

  20. 20
    Angelo Corti, Monica Giovannini, Carmen Belli, Eugenio Villa, Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF, Journal of Oncology, 2010, 2010, 1

    CrossRef

  21. 21
    Vassiliki Saloura, Petros D. Grivas, Lenalidomide: a synthetic compound with an evolving role in cancer management, Hematology, 2010, 15, 5, 318

    CrossRef